Archives
1 / 651
CM Strategy, General, Mutual Funds
Final Review: Capitalmind Passive & Equity Mutual Fund Portfolio
As we sunset Capitalmind Premium this month, this post offers a final review of two model portfolios: Capitalmind Passive and Equity Mutual Fund. It covers the ...
Stocks
Intellect Design Arena: Riding the AI Wave
Intellect Design Arena, a Chennai-based FinTech giant, leverages AI and cloud platforms like eMACH.ai and Purple Fabric to revolutionize banking, insurance, ...
Stocks
Ixigo Rides Along, As India Travels More. But, Can It Keep Up the Pace?
As India’s travel landscape transforms post-COVID with more flights, trains, and buses on the move, Ixigo has quietly become the country’s second-largest ...
General, Stocks
Bajaj Finance 3.0 : The Next Phase of Growth
Bajaj Finance’s transformation has been impressive, but the road ahead may be more nuanced. With credit demand rebounding, deposit traction improving, and ...
General, Mutual Funds
The Best ELSS Mutual Fund to Invest in 2025
ELSS funds remain a popular tax-saving investment under Section 80C, offering up to ₹1,50,000 in deductions (under the old tax regime) while providing ...
Stocks
Ganesh Housing: A GARP Opportunity
Ganesh Housing, a three-decade-old real estate player based in Ahmedabad, stands out with industry-leading margins driven by its 500-acre land bank and ...
General
Why is IndusInd Bank under pressure
IndusInd Bank’s stock is under pressure amid concerns over its derivative hedging strategy, which created an accounting mismatch between internal and ...
General
Alternative MF Picks for the Focused Portfolio
As you may already know, we will be sunsetting our research services in September 2025, also marking the end of all our premium portfolios including the ...
Stocks
Zaggle: Smarter Spend Management for Businesses
Zaggle is an innovative fintech SaaS company specializing in expense management, transforming how businesses streamline payments and manage vendor relations. ...
Stocks
Cracking the Patent Code: Natco’s Winning Formula
Natco Pharma, a leader in APIs and niche generics, faces growth challenges post-Revlimid exclusivity in FY26, with semaglutide offering long-term ...
